一季度业绩超预期，行业高景气+公司销售覆盖扩面有望驱动加速成长

Investment Rating - The report maintains a "Buy-A" investment rating with a target price of 42.02 CNY, which corresponds to a dynamic price-to-earnings ratio of 20 times for 2024 [3][28]. Core Insights - The company is expected to achieve significant revenue growth, with projected increases of 7.0%, 36.8%, and 53.4% in operating income from 2023 to 2025. Non-COVID related business revenue is forecasted to grow by 205.5%, 57.1%, and 53.4% during the same period [3][4]. - The first quarter of 2024 is anticipated to see operating income between 257 to 285 million CNY, representing a year-on-year growth of 91.06% to 111.88%. The net profit is expected to be between 138 to 154 million CNY, reflecting a growth of 156.42% to 186.15% [11][27]. - The company has developed several exclusive multi-detection products, enhancing its market presence in pediatric emergency departments and expanding its coverage in hospitals [30]. Financial Performance - The company's main revenue is projected to grow from 478.02 million CNY in 2023 to 1,002.92 million CNY by 2025. Net profit is expected to rise from 174.76 million CNY in 2023 to 424.72 million CNY in 2025 [4][3]. - The net profit margin is projected to improve significantly, reaching approximately 53.87% in Q1 2024, marking a historical high for non-COVID business [11][30]. - The company has a strong return on invested capital (ROIC) forecasted at 58.34% by 2025, indicating robust profitability [4]. Market Dynamics - The demand for respiratory pathogen testing remains high, with a notable increase in flu case monitoring compared to the previous year. The report highlights that the awareness and acceptance of pathogen testing have significantly improved post-COVID [27][15]. - The regulatory environment is supportive, with multiple directives from the National Health Commission emphasizing the necessity of pathogen detection and multi-detection testing [12][15].